Quality of Cohort Studies Reporting Post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement by Poorolajal, Jalal et al.
1
Epidemiology and Health
Epidemiology and Health
Volume: 33, Article ID: e2011005, 4 pages   
DOI 10.4178/epih/e2011005
 BRIEF COMMUNICATION Open Access
Quality of Cohort Studies Reporting Post  the Strength  ening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement
Jalal Poorolajal
1, Zahra Cheraghi
2, Amin Doosti Irani
2, Shahab Rezaeian
2
1Research Center for Health Sciences and Department of Epidemiology & Biostatistics, School of Public Health, Hamadan University of 
Medical Sciences, Hamadan; 
2Department of Epidemiology & Biostatistics, School of Public Health, Hamadan University of Medical Sciences, 
Hamadan, Iran
The quality of reporting of cohort studies published in the most prestigious scientific medical journals was in­
vestigated to indicate to what extent the items in  the Strength  ening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist are addressed. Six top scientific medical journals with high impact factor 
were selected including New England Journal of Medicine, Journal of the American Medical Associa  tion, Lan­
cet, British Medical Journal,  Archive of Internal Medicine, and Canadian Medical Association Journal. Ten co­
hort studies published in 2010 were selected randomly from each journal. The percentage of items in the STR­
OBE checklist that were addressed in each study was investigated. The total percentage of items addressed by 
these studies was 69.3 (95% confidence interval: 59.6 to 79.0). We concluded that reporting of cohort studies 
published in the most prestigious scientific medical journals is not clear enough yet. The reporting of other types 
of observational studies such as case­control and cross­sectional studies particularly those being published in 
less prestigious journals expected to be much more imprecise. 
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INTRODUCTION
Randomized trials are generally considered the gold standard 
for evaluating both the efficacy and the potential side effects of 
new therapeutic or preventive interventions in both clinical 
medicine and public health [1]. However, much of the biomedi­
cal research into the cause of diseases comes from observation­
al studies [2]. The results of these studies should be reported as 
transparently as possible “so that readers can follow what was 
planned, what was done, what was found, and what conclu-
sions were drawn” [3]. Unfortunately, reporting of observa­
tional research is neither precise nor clear enough to assess the 
strengths and weaknesses of the evidence [4, 5]. 
To improve the reporting of observational research, a group 
of experts developed a checklist of items known as the Strength­
ening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement [6]. The STROBE statement was devel­
oped in 2007 to assist authors in report writing of observational 
studies, including cohort, case­control, and cross­sectional stud­
ies, to support editors and reviewers in considering such manu­
script for publication, and to help readers in appraising published 
articles critically [3].
Concerning valuable recommendations made in this state­
ment, expected that reporting of observational studies publish­
ed after 2007 being improved enough to assess the strengths 
and weaknesses of the evidence. The present study was set up 
to investigate the quality of reporting of cohort studies pub­
lished in the most prestigious scientific medical journals and to 
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indicate to what extent the items in STROBE checklist are no­
ticed by both authors and publishers.
METHODS
We conducted a cross­sectional study and selected six top sci­
entific medical journals with high impact factor (IF) among the 
most prestigious and important medical journals indexed in in­
ternational databases. These included New England Journal of 
Medicine (N Engl J Med) (IF 50.017), Journal of the American 
Medical Association (JAMA) (IF 31.718), Lancet (IF 28.409), 
British Medical Journal (BMJ) (IF 12.827), Archives of Internal 
Medicine (Arch Intern Med) (IF 9.110), and Canadian Medical 
Association Journal (Can Med Assoc J) (IF 7.464). We were to 
include Nature and Annals of Internal Medicine in this survey, 
but they were not open access journals. 
Among the observational studies, cohort studies are much 
more expensive and take longer follow­up time than case­con­
trol and cross­sectional studies. Therefore, the results obtained 
from cohort studies are of substantially superior quality to oth­
er observational studies. In fact, cohort studies are considered 
the gold standard in observational epidemiology. Accordingly, 
we selected cohort studies, either prospective or retrospective, 
for this evaluation.
We randomly selected 10 cohort studies published in each of 
the six medical journals from January to August 2010. To do so, 
we sorted the articles from newly published articles to the old 
ones. Then, looked for the cohort studies to find ten eligible ar­
ticles. If there were not enough cohort studies, we searched se­
cond half of 2009 to obtain additional studies. Accordingly, we 
enrolled 60 cohort studies from six prestigious scientific medi­
cal journals. The studies were randomly assigned to four review­
ers through drawing lots. The reviewers independently made 
the decisions on the number of items, from the STROBE check­
list, which were addressed in the selected studies. The reviewers 
were not blinded to the names of the studies’ authors and jour­
nals. 
In order to check the reliability of the four reviewers’ judg­
ment on the quality of reporting of cohort studies, we conduct­
ed two consecutive pilot studies as follows. First, an article was 
randomly selected from JAMA. All four reviewers assessed the 
strengths and weaknesses of the evidence reported in the same 
article using the predetermined checklist of items. The disagree­
ments were discussed to reach the same perception of the check­
list in order to increase the between reviewers reliability. Then, 
the four reviewers evaluated the quality of reporting of another 
article that was randomly selected. There was no significant dif­
ferences between the reviewers’ judgment in the second pilot 
study (p=0.823).
In order to assess the validity of the reviewers’ judgments, two 
reviewers made decision on the quality of reporting of each co­
hort study independently. Any disagreements were resolved by 
adjudication with a third author.
The STROBE statement included a checklist of 22 items. In 
order to estimate the quality of reporting of cohort studies more 
accurately, we divided the items into 47 sub­items (Table 1). We 
considered three choices for each sub­item (reported/not re­
ported/not applicable). The percentage of each sub­item addre­
ssed in the selected articles was estimated. The total percentage 
for all sub­items was reported.
All statistical analysis was performed at 95% significant level 
using statistical software Stata version 10.0 (StataCorp, College 
Station, TX, USA).
RESULTS
In this survey, 60 cohort studies were selected for evaluation 
including 10 studies from the six prestigious scientific medical 
journals including: N Engl J Med, JAMA, Lancet, BMJ, Arch In­
tern Med, and Can Med Assoc J. From these, 56 studies were 
published in 2010 and four studies in 2009. The percentage of 
items and sub­items addressed by these studies are summarized 
in Table 1. The sub­items were not applicable in 7.1% (95% con­
fidence interval [CI], 1.3% to 13.0%), were not reported in 
23.6% (95% CI, 15.3% to 31.5%), and were reported in 69.3% 
(95% CI, 59.6% to 79.0%) of the cohort studies.
Of 47 sub­items investigated in this survey, nine sub­items 
were reported 100%, 22 sub­items were addressed in more 
than 90% of the studies, 28 sub­items were included in more 
than 75% of the studies, and 32 sub­items were addressed in 
more than 50% of the studies.
DISCUSSION
STROBE checklist of items provides valuable recommenda­
tions for both authors to report the results of observational stu­
dies clearly as well as for editors, reviewers, and readers to ap­
praise such reports critically [3]. On overall, almost 69.3% of 
the items and sub­items in STROBE checklist were addressed 
by cohort studies published in six top scientific medical journals 
three year after dissemination of STROBE statement. 
However, what has happened to the reports of other types of 
observational studies?  The results of the present study represent 
the reporting of cohort studies published in six prestigious sci­
entific medical journals that generally accept the well­done and 
well­written studies. However, there are numerous observation­
al studies, the results of which are published in other less fastid­3
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Table 1. Percentage of items in STROBE checklist which were addressed in reports of cohort studies published in six top scientific medical 
journals in 2010   n (%)
Item Recommendation Not applicable Not reported Reported
1a Indicate the study’s design in the title/abstract 0 (0.0) 15 (25.0) 45 (75.0)
1b Provide in the abstract an informative and balanced summary 0 (0.0) 3 (5.0) 57 (95.0)
Introduction
2 Explain the scientific background and rationale for the investigation  0 (0.0) 0 (0.0) 60 (100.0)
3 State specific objectives, including any pre-specified hypotheses 0 (0.0) 1 (1.7) 59 (98.3)
Methods 
4 Present key elements of study design early in the paper 0 (0.0) 21 (35.0) 39 (65.0)
5 Describe locations 0 (0.0) 2 (3.3) 58 (96.7)
5 Describe recruitment dates 0 (0.0) 2 (3.3) 58 (96.7)
5 Describe periods of follow-up 0 (0.0) 4 (6.7) 56 (93.3)
6a Give the eligibility criteria 0 (0.0) 4 (6.7) 56 (93.3)
6a Describe the methods of follow-up 0 (0.0) 2 (3.3) 58 (96.7)
6b Give matching criteria 54 (90.0) 0 (0.0) 6 (10.0)
6b Give number of exposed and unexposed in matched studies 52 (86.7) 5 (8.3) 3 (5.0)
7 Clearly define all outcomes 0 (0.0) 0 (0.0) 60 (100.0)
7 Clearly define all exposures 0 (0.0) 6 (10.0) 54 (90.0)
7 Clearly define all predictors 0 (0.0) 2 (3.3) 58 (96.7)
7 Clearly define all potential confounders 0 (0.0) 9 (15.0) 51 (85.0)
7 Clearly define all effect modifiers 0 (0.0) 41 (68.3) 19 (31.7)
8 Give sources of data 0 (0.0) 0 (0.0) 60 (100.0)
8 Method of measurement 0 (0.0) 1 (1.7) 59 (98.3)
9 Describe any efforts to address potential sources of bias 0 (0.0) 51 (85.0) 9 (15.0)
10 Explain how the study size was arrived at 33 (55.0) 15 (25.0) 12 (20.0)
11 Describe which groupings were chosen (if applicable) 10 (16.7) 8 (13.3) 42 (70.0)
12a Describe all statistical methods 0 (0.0) 0 (0.0) 60 (100.0)
12a Describe all statistical software 0 (0.0) 14 (23.3) 46 (76.7)
12b Describe any methods used to examine subgroups and interaction 0 (0.0) 42 (70.0) 18 (30.0)
12c Explain how missing data were addressed 0 (0.0) 33 (55.0) 27 (45.0)
12d explain how loss to follow-up was addressed 3 (5.0) 42 (70.0) 15 (25.0)
12e Describe any sensitivity analyses 3 (5.0) 44 (73.3) 0 (21.7)
Results
13a Report numbers of individuals at each stage of study 5 (8.3) 29 (48.4) 26 (43.3)
13b Give reasons for non-participation at each stage 5 (8.3) 42 (70.0) 13 (21.7)
13c Consider use of a flow diagram 0 (0.0) 51 (85.0) 9 (15.0)
14a Give characteristics of study participants 0 (0.0) 5 (8.3) 55 (81.7)
14b Indicate the number of participants with missing data 4 (6.7) 37 (61.6) 19 (31.7)
14c Summarize follow-up time 2 (3.3) 32 (53.4) 26 (43.3)
15 Report numbers of outcome events or summary measures 0 (0.0) 0 (0.0) 60 (100.0)
16a Give unadjusted estimates 0 (0.0) 23 (38.3) 37 (61.7)
16a Give confounder-adjusted estimates 1 (1.7) 6 (10.0) 53 (88.3)
16a Give estimates precision/confidence interval 0 (0.0) 2 (3.3) 58 (96.7)
16b Report category boundaries when continuous variables were categorized 8 (13.3) 7 (11.7) 45 (75.0)
16c Consider translating estimates of relative risk into absolute risk (If relevant) 21 (35.0) 32 (53.3) 7 (11.7)
17 Report other analyses done e.g., subgroups analysis and sensitivity analyses 0 (0.0) 19 (31.7) 41 (68.3)
Discussion
18 Summarize key results with reference to study objectives 0 (0.0) 0 (0.0) 60 (100.0)
19 Discuss limitations of the study 0 (0.0) 0 (0.0) 60 (100.0)
20 Give a cautious interpretation of results considering objectives 0 (0.0) 0 (0.0) 60 (100.0)
20 Explain results from similar studies 0 (0.0) 0 (0.0) 60 (100.0)
21 Discuss the generalizability of the study results 0 (0.0) 6 (10.0) 54 (90.0)
Other information
22 Give the source of funding and the role of the funders 0 (0.0) 1 (1.7) 59 (98.3)
1-22 Total  (7.1) (23.6) (69.3)
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ious peer­reviewed medical journals. Thus, it is expected that the 
quality of reporting of such studies is much poorer than what 
reported in the present study, although the result of present 
study is not desirable enough. Furthermore, cohort studies are 
much more expensive and take longer follow­up time than oth­
er types of observational studies such as case­control and cross­
sectional design. Hence, the reporting of cohort studies is gen­
erally expected to be of substantially superior quality to other 
observational studies. Accordingly, if this survey had been plan  n­
ed to assess reporting of case­control or cross­sectional studies, 
the estimated result would be much more undesirable.
We found no similar studies but one. Poorolajal et al. [7] con­
ducted a similar study in 2007 to assess the reporting of cohort 
studies before STROBE statement being issued. However, the 
design, the results, and the number of sub­items, which were 
evaluated in that study, was not comparable with that of the pre­
sent study. 
The present study had a number of limitations. First, the lim­
ited number of studies evaluated in the present study may in­
crease the possibility of random error. Second, randomly selec­
tion of cohort studies from a few prestigious medical journals 
may increase the possibility of selection bias. Third, the value of 
all sub­items was not really the same. Hence, adding up all per­
centages to estimate a summary measure might not be reason­
able, although was done to help the readers make an overall 
judgment.
This result of the present survey represents the quality of the 
reporting of cohort studies in top scientific medical journals. 
Hence, we can generalize the results of this survey neither to 
other types of observational studies nor to the publication of 
less fastidious peer­reviewed medical journals.
We concluded that reporting of cohort studies published in 
the most prestigious scientific medical journals is not clear and 
desirable enough yet. The reporting of other types of observa­
tional studies such as case­control and cross­sectional studies 
particularly those being published in less fastidious peer­review­
ed journals is expected to be much more imprecise. This issue 
should be the focus of the both authors’ and editors’ special at­
tention when reporting and/or reviewing the reports of obser­
vational studies.
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